Global Blood Therapeutics, Inc. Logo
Clinical Education ExchangeExpert insights for healthcare professionals
Expert insights for healthcare professionals

Learn more about Oxbryta from SCD medical experts who treat patients with sickle cell disease

Are you a practicing healthcare professional in the United States? Sign up for a complimentary 30-60 minute online session with one of your peers.

Personalized sessions

One-on-one meetings that are just for you.

On your time

Choose a date and time that fits your schedule.

You choose the healthcare professional

Select from our panel of medical experts.

You pick the session topic

Choose a presentation and get your Oxbryta questions answered.

Ready to schedule a session?

Are you a US healthcare professional with a valid National Provider Identifier (NPI) who treats patients with sickle cell disease?

Meet the medical experts

Disclosure: All healthcare professionals are paid by Global Blood Therapeutics for participating in these online sessions.

Photo of Pat Adams-Graves, MD
Pat Adams-Graves, MD
Professor of Medicine
Memphis, Tennessee
Dr. Adams-Graves earned her medical degree from the University of Louisville in Kentucky and served her internship and residency at the University of Louisville/Humana University Hospital. She held fellowship in hematology/oncology at the University of Tennessee, Memphis/Veterans Administration Hospital/Baptist Memorial Hospital in Memphis. Dr. Adams-Graves is certified in internal medicine and clinical pathology. She has been involved with 15 clinical trials studying sickle cell disease as an investigator, as well as published more than 30 articles in peer-reviewed medical journals and 40 abstracts/posters at major medical conferences. In addition, Dr. Adams-Graves serves as a reviewer for *Journal of Hematology*.
Read Bio
Photo of Alan Anderson, MD
Alan Anderson, MD
Assistant Professor of Clinical Pediatrics
Greenville, South Carolina
Dr. Anderson is an Assistant Professor of Clinical Pediatrics, specializing in sickle cell disease (SCD). He received his medical degree from the Medical University of South Carolina in Charleston, where he completed a residency in general pediatrics. He completed a fellowship at Emory University School of Medicine in Atlanta, Georgia in pediatric hematology, oncology, and bone marrow transplantation. Dr. Anderson has lectured on SCD and pediatric oncology in the United States and internationally. His articles have appeared in the *American Journal of Transplantation*, *Blood Transfusion in Clinical Medicine*, and the *Journal of Global Oncology*, including a recent report on his work in establishing a pediatric hematology-oncology program in Botswana.
Read Bio
Photo of Tammuella Chrisentery-Singleton, MD
Tammuella Chrisentery-Singleton, MD
Chief of Pediatric Hematology
Madison, Mississippi
Dr. Chrisentery-Singleton provides care for children and adults with sickle cell disease, hemophilia, von Willebrand disease, and other rare bleeding disorders. She received her medical degree from Louisiana State University School of Medicine and completed a residency, as well as a clinical fellowship in pediatric hematology/oncology, at Johns Hopkins University. She completed the Baxter/National Hemophilia Foundation clinical fellowship program at Tulane University School of Medicine. A principal investigator for more than 30 clinical trials, Dr. Chrisentery-Singleton has published more than 10 articles and abstracts in peer-reviewed journals such as the *Journal of the American Board of Family Medicine*, *Pediatric Blood and Cancer*, the *Chinese Journal of Cancer Research*, and *Hemophilia*. She has been a speaker at numerous national and international grand rounds and symposia on thrombosis, hemostasis, rare bleeding disorders, and pediatric hematology/oncology.
Read Bio
Photo of Coretta Collins, MSN, FNP-BC
Coretta Collins, MSN, FNP-BC
Family Nurse Practitioner
Birmingham, Alabama
Ms. Collins is a Family Nurse Practitioner who treats hematology and oncology patients. She received her nursing degree from the University of Alabama, Huntsville, and her master's degree from the college's Birmingham location. From there, she held several positions, including patient care associate, relief charge nurse, staff RN, and clinical coordinator. Since developing a clinical interest in hematology and oncology as a nurse practitioner, Ms. Collins has delivered lectures on cancer awareness, chemotherapy treatments, and clinical indicators of hospice patient decline at local conferences throughout the state.
Read Bio
Photo of Richard Drachtman, MD
Richard Drachtman, MD
Pediatric Hematologist/Oncologist
New Brunswick, New Jersey
After earning his medical degree from Chicago Medical School in Illinois, Dr. Drachtman completed his pediatric internship and residencies at North Shore University Hospital in New York. He then completed a pediatric hematology/oncology fellowship at Mount Sinai Medical Center in New York City. Certified by the American Board of Pediatrics, with specialty certification in pediatric hematology/oncology, Dr. Drachtman has a special interest in sickle cell disease (SCD). Dr. Drachtman serves as a reviewer for a number of journals, including *Clinical Cancer Research*, *Journal of Clinical Oncology*, *Journal of Pediatrics*, *Journal of Pediatric Hematology/Oncology*, and *Pediatric Blood and Cancer*. An active researcher, Dr. Drachtman has served as principal investigator for trials in hematologic disorders, including SCD. He has authored more than 50 peer-reviewed publications and has lectured extensively throughout the New York Tri-state area.
Read Bio
Photo of Nayf Edrees, MD
Nayf Edrees, MD
Pediatric Hematologist/Oncologist
Boca Raton, Florida
Dr. Edrees is a Professor of Clinical Biomedical Science/Integrated Medical Science and serves as a pediatric hematologist/oncologist through multiple hospitals. He earned his medical degree from the University of Aleppo in Syria and completed internship and residency requirements in pediatrics at the University of Illinois at Chicago. Dr. Edrees completed a fellowship in pediatric hematology/oncology at the University of Alabama at Birmingham and is board certified in pediatrics. His research has been published in more than 15 peer-reviewed journal articles, and he has presented abstracts and posters at numerous medical conferences.
Read Bio
Photo of William Ershler, MD
William Ershler, MD
Director of Hematology
Falls Church, Virginia
Dr. Ershler received his medical degree from the State University of New York Upstate Medical University. He completed a residency at the University of Wisconsin, continuing there with a clinical fellowship in human oncology and a research fellowship in hematology, working primarily in pediatrics. A lifetime focus on geriatrics, with special interest in hematologic conditions related to the aging process, has characterized Dr. Ershler's clinical and research career. He has served on study sections pertaining to aging, aging systems, and geriatrics. The author of more than 300 articles, he has also authored a textbook chapter for *Hematology: Basic Principles and Practice* and edited several books related to geriatric oncology and anemia.
Read Bio
Photo of Amber Flaherty, MD
Amber Flaherty, MD
Hematologist/Oncologist
Phoenix, Arizona
Dr. Flaherty earned a medical degree from St. George's University in Grenada. She completed her residency in internal medicine at the University of Texas Health Science Center, followed by a fellowship in hematology/oncology at the University of San Francisco Moffitt Cancer Center. Dr. Flaherty has published papers in *Urologic Oncology* and *Clinical Genitourinary Cancer*, with topics including immunotherapy treatments in renal cell cancer; patient outcomes in metastatic renal cell carcinoma with dialysis for end-stage renal disease; and human papillomavirus in penile cancer. She has presented her research at ASCO annual meetings.
Read Bio
Photo of Renee Gardner, MD
Renee Gardner, MD
Professor of Pediatrics
New Orleans, Louisiana
Dr. Gardner received her medical degree from Harvard Medical School and completed her residency in pediatrics at the State University of New York (SUNY), Buffalo. She completed fellowships at SUNY Buffalo, The Jackson Laboratory in Bar Harbor, Maine, and at the National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, Maryland. An avid researcher, Dr. Gardner is currently participating in 3 ongoing clinical trials. She has spoken at numerous grand rounds on sickle cell disease and cancer therapies, as well as at national and international conferences. She has presented nearly 100 abstracts and published more than 50 peer-reviewed articles and book chapters on topics related to pediatric hematology and oncology.
Read Bio
Photo of Christine Hoehner-Cooper, MSN, RN, NP-C
Christine Hoehner-Cooper, MSN, RN, NP-C
Nurse Practitioner
Oakland, California
Ms. Hoehner-Cooper is a Nurse Practitioner in California. She earned her undergraduate nursing degree from San Diego State University in California and her Master of Science in nursing from Holy Names University in Oakland, before completing a fellowship at Samuel Merritt University School of Nursing. Serving as a coinvestigator for multiple clinical trials studying various treatments for patients with sickle cell disease, Ms. Hoehner-Cooper has coauthored numerous abstracts and posters published in peer-reviewed medical literature, presented at medical conferences and was coauthor of an article published in a peer-reviewed journal. She has also been an invited lecturer at various community health events.
Read Bio
Photo of Modupe Idowu, MD
Modupe Idowu, MD
Associate Professor of Medicine and Hematology
Houston, Texas
Dr. Idowu is Associate Professor and Medical Director in the Division of Hematology. She earned her medical degree from Texas Tech University School of Medicine and completed a residency in internal medicine at Texas Tech University Health Sciences Center. She completed a fellowship in hematology at the University of Florida. Dr. Idowu's clinical interests include sickle cell anemia, other anemias, thrombocytopenia, leukopenia, myelodysplastic syndrome, bone marrow disorders, and multiple myeloma. In addition to serving as an investigator for more than 12 clinical trials, Dr. Idowu is a reviewer for the journal *Scientific Reports*.
Read Bio
Photo of Elyse Mandell, APRN, BC
Elyse Mandell, APRN, BC
Nursing Director, Division of Hematology
Boston, Massachusetts
Ms. Mandell is a hematology Nursing Director and Nurse Practitioner. She is also the Program Manager for an Anticoagulation Management Service. A graduate of Smith College in Massachusetts, Ms. Mandell earned her nursing degree, Master of Science in nursing, and certification as an adult nurse practitioner from MGH Institute for Health Professions in Boston. Ms. Mandell is dedicated to educating healthcare professionals on caring for patients with sickle cell disease (SCD) and related complications. She has lectured on anemia management, patient care, and the transition from pediatric to adult care for SCD at nurse practitioner conferences and quarterly in-service meetings for newly hired nurses, as well as at conferences held by the Sickle Cell Disease Association of America.
Read Bio
Photo of Caterina Minniti, MD
Caterina Minniti, MD
Professor of Clinical Medicine and Pediatrics
New York, New York
Dr. Minniti is Professor of Clinical Medicine and Pediatrics and Director of a Sickle Cell Center in New York. Her objective is to develop pathogenetically based therapeutic approaches for preventing and treating sickle cell disease (SCD)-related end-organ damage. Dr. Minniti earned her medical degree from the University of Catania School of Medicine in Sicily, followed by a pediatric residency at the University of Maryland in Baltimore and a pediatric hematology/oncology fellowship at Johns Hopkins University Hospital and at the National Institutes of Health. Dr. Minniti's research focuses on understanding mechanisms that lead to end-organ damage to identify early biomarkers and targeted therapies. Her interests have ranged from stroke to pulmonary hypertension and, most recently, to leg ulcers, as they represent a window into the vasculopathy in SCD. She has been a member of the Adult Sickle Cell Network since 2008. She has co-authored 3 textbook chapters and more than 125 peer-reviewed articles, mostly on SCD, and is associate editor of the *American Journal of Hematology* and reviewer for the *New England Journal of Medicine*, *JAMA,* and *Blood.*
Read Bio
Photo of Ify Osunkwo, MD, MPH
Ify Osunkwo, MD, MPH
Clinical Associate Professor of Medicine
Chapel Hill, North Carolina
Dr. Osunkwo earned her medical degree from the University of Nigeria College of Medical Sciences and Dentistry. She completed an internship at the University of Medicine and Dentistry of New Jersey and completed fellowships in pediatric hematology/oncology and pediatric bone marrow transplantation research at Columbia University College of Physicians and Surgeons in New York City. She completed an additional fellowship, in outpatient hematology/oncology clinical and consultation service, at St. Joseph's Children's Hospital in New Jersey. She is board certified in pediatric medicine and pediatric hematology/oncology. Dr. Osunkwo has served as an investigator for nearly 20 clinical trials studying sickle cell disease and published more than 35 articles in the peer-reviewed medical literature.
Read Bio
Photo of Connie Piccone, MD
Connie Piccone, MD
Associate Professor, Department of Pediatrics
Cleveland, Ohio
Dr. Piccone is Associate Professor in the Department of Pediatrics and Clinical Director of a Sickle Cell Anemia Center in Ohio. She received her medical degree from Drexel University School of Medicine, followed by a residency in pediatrics at UH Rainbow Babies and Children's Hospital, a fellowship in hematology/oncology at Children's Hospital of Philadelphia, and a Clinical Research Certificate Program in clinical epidemiology and biostatistics at the University of Pennsylvania. Dr. Piccone's research in sickle cell disease (SCD) has involved her in numerous studies, including ENGAGE, TWiTCH, SITT, EPIC, and DOVE. Her research has been published in the *New England Journal of Medicine*, *PLoS One*, *American Journal of Hematology*, and *Lancet*, and she has authored 2 book chapters on SCD for *Netter's Pediatrics* and *Sickle Cell Nephropathy in Children*. She is a member of the Sickle Cell Providers Network and Foundation for SCD Research. Dr. Piccone has been recognized for her expertise at the state level, serving as past Chair of the Sickle Cell Advisory Committee for the Ohio Sickle Cell and Health Association.
Read Bio
Photo of Bridgette Pierre, MSN, APRN, FNP-BC
Bridgette Pierre, MSN, APRN, FNP-BC
Family Nurse Practitioner
Baton Rouge, Louisiana
Mrs. Pierre earned her undergraduate nursing degree and Master of Science degree in nursing from Southern University and A&M College in Baton Rouge, Louisiana. In her clinical role, Mrs. Pierre monitors, screens, and promotes health and maintenance of adult patients with sickle cell disease, administering appropriate pain management and prophylaxis in the inpatient and outpatient settings. Promoting sickle cell awareness and education through outreach efforts, Mrs. Pierre has been co-chair of her hospital's annual Sickle Cell Awareness Day for the past 3 years, has participated in local health fairs, and is working to organize "Sickle Cell Sabbath," which will involve visits to local churches with the mission of increasing African American blood donors.
Read Bio
Photo of Santosh Saraf, MD, MS
Santosh Saraf, MD, MS
Associate Professor of Medicine
Chicago, Illinois
Dr. Saraf earned his medical degree from Temple University School of Medicine in Pennsylvania and fulfilled his internship, internal medicine residency, and hematology/oncology fellowship requirements at the University of Illinois at Chicago Medical Center. In addition, he completed a Master of Science degree in clinical and translational research at the University of Chicago School of Public Health. He is board certified in hematology and medical oncology. Dr. Saraf serves as a reviewer for multiple peer-reviewed medical journals, such as *Blood*, *Journal of the American Society of Nephrology*, *American Journal of Clinical Nutrition*, *American Journal of Hematology*, *PLOS One*, and *Frontiers in Oncology*, and has authored 60 articles published in such journals.
Read Bio
Photo of Nirmish Shah, MD
Nirmish Shah, MD
Associate Professor
Durham, North Carolina
Dr. Shah's practice and research focuses on treating children and adults with sickle cell disease. When working with children, he focuses on teaching them about their condition and how to transition successfully to living with the disease as an adult. Dr. Shah earned his medical degree from the American University of the Caribbean, prior to fulfilling internship, residency, and fellowship requirements at East Carolina University. He also completed a Clinical Research Training Program at Duke University. Dr. Shah is board certified in pediatrics and pediatric hematology/oncology. For all patients, he provides the medical, social, and psychological support they need to remain healthy. His research aims to increase engagement of patients with sickle cell with their own care using mobile technology. Through the use of applications, he hopes to help patients, specifically children, better manage their symptoms and medications.
Read Bio
Photo of Wally Smith, MD
Wally Smith, MD
Florence Neal Cooper Smith Professor of Sickle Cell Disease
Richmond, Virginia
Dr. Smith earned his medical degree from the University of Alabama School of Medicine, prior to completing an internship at University of Alabama Hospitals. He completed his residency at University of Tennessee Hospitals and is board certified in internal medicine. Dr. Smith is best known as Principal Investigator of the landmark Pain in Sickle Cell Epidemiology Study (PiSCES), the largest and most detailed adult cohort study of sickle cell disease (SCD) pain. Author of more than 130 publications, Dr. Smith has served as an investigator on more than 55 externally funded grants and contracts. He is Principal Investigator of likely the first-ever randomized controlled trial of implementation science in SCD, Start Healing in Patients with Hydroxyurea (SHiP HU). Dr. Smith also participated in the published evidence-based classification systems for acute and chronic SCD pain.
Read Bio
Photo of Kusum Viswanathan, MD
Kusum Viswanathan, MD
Director of Pediatric Hematology/Oncology
New York, New York
Dr. Viswanathan is Director of the Division of Pediatric Hematology/Oncology, Chair of the Department of Pediatrics, and President of a Hospital Medical Board in Brooklyn, New York. She earned her medical degree from the All-India Institute of Medical Sciences in New Delhi, India, prior to fulfilling residency requirements in pediatrics at Long Island College Hospital in New York, where she also completed a fellowship in pediatric hematology/oncology. Dr. Viswanathan is board certified to practice pediatric medicine and pediatric hematology/oncology. Dr. Viswanathan's research has been published in multiple peer-reviewed medical journals, and she has presented posters and abstracts throughout the country. In addition, she has served as an invited lecturer at nationwide symposia, including as a keynote speaker.
Read Bio
Photo of Ahmar Zaidi, MD
Ahmar Zaidi, MD
Sickle Cell Physician/Hematologist
Detroit, Michigan
Dr. Zaidi earned his medical degree from the Medical University of the Americas in Nevis, West Indies. He served a residency at Oakland University William Beaumont School of Medicine in Michigan and completed a fellowship at Children's Hospital of Michigan. Board certified in pediatrics, he also holds a subspecialty certification in pediatric hematology/oncology. Dr. Zaidi has presented posters at annual meetings of the American Society of Hematology and American Society of Pediatric Hematology/Oncology. He has also given podium presentations at the Foundation for Sickle Cell Research Annual Meeting and the European Red Cell Society Meeting. Dr. Zaidi has many peer-reviewed articles and abstracts to his credit.
Read Bio
INDICATIONS AND USAGE

Oxbryta is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Contraindications

Oxbryta is contraindicated in patients with a history of serious drug hypersensitivity reaction to voxelotor or excipients.

Warnings and precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions after administration of Oxbryta have occurred in <1% of patients treated. Clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia.

If hypersensitivity reactions occur, discontinue Oxbryta and administer appropriate medical therapy. Do not reinitiate Oxbryta in patients who experience these symptoms with previous use.

Laboratory Test Interference

Oxbryta administration may interfere with measurement of Hb subtypes by (HbA, HbS, and HbF) HPLC. If precise quantitation of Hb species is required, chromatography should be performed when the patient is not receiving Oxbryta therapy.

Adverse reactions

Clinical Trials Experience

Serious adverse reactions occurred in 3% (3/88) of patients receiving Oxbryta 1,500 mg, which included headache, drug hypersensitivity, and pulmonary embolism occurring in 1 patient each.

Adverse Reactions (≥10%) in patients receiving Oxbryta with a difference of >3% compared to placebo: Headache (26% vs. 22%), Diarrhea (20% vs. 10%), Abdominal Pain (19% vs. 13%), Nausea (17% vs. 10%), Fatigue (14% vs. 10%), Rash (14% vs. 10%), and Pyrexia (12% vs. 7%).

Drug interactions

Sensitive CYP3A4 Substrates

Voxelotor increased the systemic exposure of midazolam (a sensitive CYP3A4 substrate). Avoid co-administration with sensitive CYP3A4 substrates with a narrow therapeutic index. If unavoidable, consider dose reduction of the CYP3A4 substrate(s).

Strong CYP3A4 Inhibitors or Fluconazole

Co-administration of strong CYP3A4 inhibitors or fluconazole may increase voxelotor plasma concentrations and may lead to increased toxicity. Avoid co-administration of strong CYP3A4 inhibitors or fluconazole. Decrease Oxbryta dosage if unavoidable.

Strong or Moderate CYP3A4 Inducers

Co-administration of strong or moderate CYP3A4 inducers may decrease voxelotor plasma concentrations and may lead to reduced efficacy. Avoid co-administration of strong or moderate CYP3A4 inducers. Increase the Oxbryta dosage if unavoidable.

USE IN SPECIFIC POPULATIONS

Lactation

Because of the potential for serious adverse reactions in the breastfed child, including changes in the hematopoietic system, advise patients not to breastfeed while taking Oxbryta and for at least 2 weeks after the last dose.

Recommended Dosage for Hepatic Impairment

Severe hepatic impairment increases voxelotor exposures. Reduce dose to 1,000 mg orally once daily for severe hepatic (Child Pugh C) impairment.

INDICATIONS AND USAGE

Oxbryta is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Contraindications

Oxbryta is contraindicated in patients with a history of serious drug hypersensitivity reaction to voxelotor or excipients.

Warnings and precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions after administration of Oxbryta have occurred in <1% of patients treated. Clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia.

If hypersensitivity reactions occur, discontinue Oxbryta and administer appropriate medical therapy. Do not reinitiate Oxbryta in patients who experience these symptoms with previous use.

Laboratory Test Interference

Oxbryta administration may interfere with measurement of Hb subtypes by (HbA, HbS, and HbF) HPLC. If precise quantitation of Hb species is required, chromatography should be performed when the patient is not receiving Oxbryta therapy.

Adverse reactions

Clinical Trials Experience

Serious adverse reactions occurred in 3% (3/88) of patients receiving Oxbryta 1,500 mg, which included headache, drug hypersensitivity, and pulmonary embolism occurring in 1 patient each.

Adverse Reactions (≥10%) in patients receiving Oxbryta with a difference of >3% compared to placebo: Headache (26% vs. 22%), Diarrhea (20% vs. 10%), Abdominal Pain (19% vs. 13%), Nausea (17% vs. 10%), Fatigue (14% vs. 10%), Rash (14% vs. 10%), and Pyrexia (12% vs. 7%).

Drug interactions

Sensitive CYP3A4 Substrates

Voxelotor increased the systemic exposure of midazolam (a sensitive CYP3A4 substrate). Avoid co-administration with sensitive CYP3A4 substrates with a narrow therapeutic index. If unavoidable, consider dose reduction of the CYP3A4 substrate(s).

Strong CYP3A4 Inhibitors or Fluconazole

Co-administration of strong CYP3A4 inhibitors or fluconazole may increase voxelotor plasma concentrations and may lead to increased toxicity. Avoid co-administration of strong CYP3A4 inhibitors or fluconazole. Decrease Oxbryta dosage if unavoidable.

Strong or Moderate CYP3A4 Inducers

Co-administration of strong or moderate CYP3A4 inducers may decrease voxelotor plasma concentrations and may lead to reduced efficacy. Avoid co-administration of strong or moderate CYP3A4 inducers. Increase the Oxbryta dosage if unavoidable.

USE IN SPECIFIC POPULATIONS

Lactation

Because of the potential for serious adverse reactions in the breastfed child, including changes in the hematopoietic system, advise patients not to breastfeed while taking Oxbryta and for at least 2 weeks after the last dose.

Recommended Dosage for Hepatic Impairment

Severe hepatic impairment increases voxelotor exposures. Reduce dose to 1,000 mg orally once daily for severe hepatic (Child Pugh C) impairment.